Our findings strongly suggest that the JNK pathway acts as a tumour suppressor in ER+ breast cancer, and that JNK pathway status may be a biomarker of response to combination endocrine and CDK4/6 inhibitor therapy. Here, CDK4 is linked to breast cancer.